Scholarlink

Background <p>The C‑reactive protein–triglyceride glucose index (CTI), a composite marker of systemic inflammation and metabolic status, has been associated with cardiovascular and cerebrovascular risk. Its role in central retinal artery occlusion (CRAO) and subsequent adverse outcomes is unclear.</p> Methods <p>In this cohort study, 122 CRAO patients and 488 matched controls who underwent coronary angiography without coronary artery disease were analyzed. CTI was calculated as 0.412 × ln [CRP (mg/L) + 0.5 × ln [TG × FPG(mg/dL)]. Logistic regression adjusted for demographic, clinical, laboratory, and medication variables was used to explore the relationship between CTI and the risk of CRAO. Restricted cubic spline models assessed the dose–response relationship between CTI and CRAO risk. The primary endpoint was CRAO and the secondary endpoint was major adverse cardiovascular and cerebrovascular events (MACCEs) during the 36‑month follow‑up.</p> Results <p>Higher CTI was independently associated with CRAO (adjusted OR = 1.46, 95% CI 1.14–1.88; <i>P</i> = 0.003). Restricted cubic spline analysis identified a CTI threshold of 9.810. CRAO patients with CTI &gt; 9.810 had a higher incidence of MACCEs (31.1% vs. 10.1%, <i>P</i> &lt; 0.001), particularly acute coronary syndromes (20.3% vs. 7.1%, <i>P</i> &lt; 0.001). In subgroup analysis, CRAO patients with CTI &gt; 9.810 had the highest MACCEs rate (40.0%) and significantly greater risk of all‑cause death, stroke, and acute coronary syndromes (all adjusted <i>P</i> &lt; 0.05) compared with other groups. Time‑to‑event analysis revealed that among all groups, CRAO patients with CTI &gt; 9.810 had the shortest median time to MACCEs occurrence at 6&#xa0;months (IQR,  4–11).</p> Conclusions <p>Elevated CTI is independently associated with increased CRAO risk and predicts higher adverse MACCEs outcomes, suggesting CTI as a potential biomarker for risk stratification and secondary prevention in CRAO patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

CRP–TyG index and risk of new‑onset central retinal artery occlusion and subsequent major adverse cardiovascular and cerebrovascular events: a propensity score‑matched cohort study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月12日

查看全文
  • Hang Liu,
  • Fangyuan Zhu,
  • Hao Xie,
  • Shuo Li,
  • Faxi Wang,
  • Liang Hu,
  • Ting Chen,
  • Xuan Xiao

摘要

Background

The C‑reactive protein–triglyceride glucose index (CTI), a composite marker of systemic inflammation and metabolic status, has been associated with cardiovascular and cerebrovascular risk. Its role in central retinal artery occlusion (CRAO) and subsequent adverse outcomes is unclear.

Methods

In this cohort study, 122 CRAO patients and 488 matched controls who underwent coronary angiography without coronary artery disease were analyzed. CTI was calculated as 0.412 × ln [CRP (mg/L) + 0.5 × ln [TG × FPG(mg/dL)]. Logistic regression adjusted for demographic, clinical, laboratory, and medication variables was used to explore the relationship between CTI and the risk of CRAO. Restricted cubic spline models assessed the dose–response relationship between CTI and CRAO risk. The primary endpoint was CRAO and the secondary endpoint was major adverse cardiovascular and cerebrovascular events (MACCEs) during the 36‑month follow‑up.

Results

Higher CTI was independently associated with CRAO (adjusted OR = 1.46, 95% CI 1.14–1.88; P = 0.003). Restricted cubic spline analysis identified a CTI threshold of 9.810. CRAO patients with CTI > 9.810 had a higher incidence of MACCEs (31.1% vs. 10.1%, P < 0.001), particularly acute coronary syndromes (20.3% vs. 7.1%, P < 0.001). In subgroup analysis, CRAO patients with CTI > 9.810 had the highest MACCEs rate (40.0%) and significantly greater risk of all‑cause death, stroke, and acute coronary syndromes (all adjusted P < 0.05) compared with other groups. Time‑to‑event analysis revealed that among all groups, CRAO patients with CTI > 9.810 had the shortest median time to MACCEs occurrence at 6 months (IQR,  4–11).

Conclusions

Elevated CTI is independently associated with increased CRAO risk and predicts higher adverse MACCEs outcomes, suggesting CTI as a potential biomarker for risk stratification and secondary prevention in CRAO patients.